Braveheart Bio Announces Late-breaking Presentation Of 52-Week Extension Data For BHB-1893 In Obstructive HCM At The American Heart Association Scientific Sessions, November 6-9; Will Also Host Webinar

Oral Abstract Presentation

Title: HRS/BHB-1893, a Next-Generation Cardiac Myosin Inhibitor, Improves Indices of Diastolic Function in Non-Obstructive Hypertrophic Cardiomyopathy: Evidence From in vitro Studies and Patients

Presenter: Carlos del Rio, Ph.D., Senior Vice President, Cardiovascular Research & Translational Science, Braveheart Bio

Date: Friday, November 6, 2026

Session Title: Hypertrophic Cardiomyopathy Medical Society Abstract Oral Presentations

Session Time: 9:45 AM – 10:45 AM CT

Presentation Time: 10:15 AM – 10:25 AM CT

Location: Room S406A, McCormick Place

Late-Breaking Oral Abstract Presentation

Title: Long-Term Efficacy and Safety of BHB/HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy: Results From the 52-Week Extension Period

Presenter: Xueyi Wu, M.D., Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China​

Date: Friday, November 6, 2026

Session Title: Hypertrophic Cardiomyopathy Medical Society Late Breaking Oral Abstracts

Session Time: 2:15 PM – 3:15 PM CT

Presentation Time: 2:15 PM – 2:25 PM CT

Location: Room S406A, McCormick Place

Braveheart Bio, Inc. (NASDAQ:BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced that it will host an investor and analyst webinar on Friday, November 6, 2026, from 4:35 p.m. to 6:05 p.m. ET. The event will feature remarks on Braveheart Bio's cardiac myosin inhibitor program and the global clinical development of BHB-1893 in patients with obstructive HCM and non-obstructive HCM from Management and the following speakers:

• Anjali Owens, M.D., Associate Professor of Medicine and Medical Director, Penn Center for Inherited Cardiovascular Disease, Perelman School of Medicine at the University of Pennsylvania
• Mariko Harper, M.D., Medical Director, Hypertrophic Cardiomyopathy Center of Excellence, Virginia Mason Franciscan Health

A live question-and-answer session will follow the formal presentations. 

Interested parties should register for the event at the following link: HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor. A live webcast of the event will be accessible by visiting the Investor Relations section of the Braveheart Bio website at https://ir.braveheart.bio/. A link to the webcast replay will be available in a temporary archive following the event.